The North America Dementia Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2024-2031).
The US market dominated the North America Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$7.85 billion by 2031. The Canada market is experiencing a CAGR of 9.3% during (2024 - 2031). Additionally, The Mexico market would witness a CAGR of 8.3% during (2024 - 2031).
Dementia is a comprehensive collection of brain diseases that cause a significant and often gradual erosion of an individual's ability to think and remember, thereby significantly affecting their daily life. As one of the most prevalent forms of dementia, Alzheimer's disease accounts for approximately 60-70% of cases. Additional types of dementia include frontotemporal dementia, vascular dementia, and Lewy body dementia.
The prevalence of dementia is increasing at a rapid pace, which requires substantial progress in its treatment and management as the global population ages. This burgeoning prevalence, coupled with the immense societal and economic burden it imposes, has catalyzed the development of the dementia treatment market. Numerous services and products are currently available on the market with the intention of diagnosing, treating, and managing dementia-related conditions. These conditions include Alzheimer's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia, among others.
Mexico is also witnessing a rise in the demand for dementia treatment due to the increasing prevalence of dementia and ongoing research efforts. According to a study published by the National Institute of Public Health (INSP) of Mexico, the number of people living with dementia in Mexico is expected to grow from approximately 800,000 in 2020 to over 1.5 million by 2050. The aging population, as well as increased life expectancy, are the primary factors contributing to this increase. Hence, the region will present lucrative growth opportunities for the market throughout the forecast period.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$7.85 billion by 2031. The Canada market is experiencing a CAGR of 9.3% during (2024 - 2031). Additionally, The Mexico market would witness a CAGR of 8.3% during (2024 - 2031).
Dementia is a comprehensive collection of brain diseases that cause a significant and often gradual erosion of an individual's ability to think and remember, thereby significantly affecting their daily life. As one of the most prevalent forms of dementia, Alzheimer's disease accounts for approximately 60-70% of cases. Additional types of dementia include frontotemporal dementia, vascular dementia, and Lewy body dementia.
The prevalence of dementia is increasing at a rapid pace, which requires substantial progress in its treatment and management as the global population ages. This burgeoning prevalence, coupled with the immense societal and economic burden it imposes, has catalyzed the development of the dementia treatment market. Numerous services and products are currently available on the market with the intention of diagnosing, treating, and managing dementia-related conditions. These conditions include Alzheimer's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia, among others.
Mexico is also witnessing a rise in the demand for dementia treatment due to the increasing prevalence of dementia and ongoing research efforts. According to a study published by the National Institute of Public Health (INSP) of Mexico, the number of people living with dementia in Mexico is expected to grow from approximately 800,000 in 2020 to over 1.5 million by 2050. The aging population, as well as increased life expectancy, are the primary factors contributing to this increase. Hence, the region will present lucrative growth opportunities for the market throughout the forecast period.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Eisai Co., Ltd.
- Eli Lilly And Company
- F.Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Market Report Segmentation
By Type- Diagnosis
- Imaging Techniques
- Cognitive Assessment Tools
- Genetic Testing
- Biomarker Analysis
- Others
- Drugs
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
- Oral
- Transdermal Patch
- Injectable
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson Disease Dementia
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America Dementia Treatment Market by Type
Chapter 5. North America Dementia Treatment Market by Dementia Drugs Route of Administration
Chapter 6. North America Dementia Treatment Market by Dementia Drugs Distribution Channel
Chapter 7. North America Dementia Treatment Market by Indication
Chapter 8. North America Dementia Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Eisai Co., Ltd.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Methodology
LOADING...
